EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cholesterol transporters and immune-metabolic features in patients with metastatic renal cell carcinoma receiving immunotherapy combinations

Giulia Claire Giudice, Hassan Mohammed Abushukair, Giulia Mazzaschi, Pietro Tuttobene, Michele Maffezzoli, Letizia Gnetti, Nicoletta Campanini, Giacomo Iovane, Fabiana Perrone, Monica Pluchino, Elena Rapacchi, Giada Pinterpe, Stefano Travaglini, Rosedwige Marchitelli, Tae Gyu Oh, Abdul Rafeh Naqash, Matteo Santoni, Elisa Araldi, Roberto Pili, Riccardo Perrone, Francesco Potì, Rossana Berardi, Federica Pecci, Sebastiano Buti

The Oncologist · 2026-11-06

DOI: 10.1093/oncolo/oyag430 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Despite improved outcomes with immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC), reliable biologically-driven prognostic markers remain needed. The CHOMET study evaluated tumor ABCA1/ABCG1 expression and their association with systemic lipid parameters, nutritional status, nephrectomy status and survival outcomes. Methods CHOMET was a retrospective observational biomarker study including mRCC patients undergoing first-line ICI-combinations. Tumor ABCA1 and ABCG1 expressions were assessed by immunohistochemistry (IHC). Serum total cholesterol (TC), triglycerides (TG), and the Controlling Nutritional Status score (CONUT) were collected. Publicly available transcriptomic datasets were used for exploratory bulk RNA-seq, immune deconvolution, and single-cell analyses. Results Among 86 patients (46 with IHC), high ABCA1 and ABCG1 expression was associated with shorter overall survival (OS, p = 0.003 and p = 0.01) and progression-free survival (PFS, p = 0.05 and p = 0.08). A composite nephrectomy-cholesterol score and a lower CONUT score were both significantly associated with improved PFS and OS. Exploratory bulk RNA-seq analyses suggested that high ABCA1 expression correlated with features of an immunosuppressive microenvironment enriched in M2 macrophages and depleted of CD8+ T cells, whereas high ABCG1 expression correlated with increased regulatory T cells. Exploratory single-cell analyses from four patients showed ABCA1 and ABCG1 expression across tumor-associated macrophages and tumor cells, with donor-specific pathway enrichment patterns involving immune signaling and cholesterol metabolism-related transcriptional programs. Conclusions ABCA1 and ABCG1 expression levels were associated with poorer outcomes in mRCC treated with ICI combinations and support a link between cholesterol transport programs and an immunosuppressive, metabolically reprogrammed tumor microenvironment.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →